Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: Focusing on an effect of the number of mediastinal lymph node stations involved

Interactive Cardiovascular and Thoracic Surgery

Volumn 7, Issue 4, 2008, Pages 573-577

  Matsuguma, Haruhisa ^a   Nakahara, Rie ^a   Ishikawa, Yoshinori ^a   Suzuki, Haruko ^a   Inoue, Koichi ^a   Katano, Susumu ^a   Yokoi, Kohei ^a  

^a TOCHIGI CANCER CENTER   (Japan)

Author keywords

Mediastinal lymph node metastases; NSCLC; Postoperative radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 49249138420     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2007.174342     Document Type: Article

References (14)

1. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-263.
2. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Tsuboi M. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 2001;122:803-808.
3. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006.
4. Bogart JA, Aronowitz JN. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy. Clin Cancer Res 2005;11:5004s-5010s.
5. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
6. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978;76:832-839.
7. Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986;315:1377-1381.
8. Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K, Lagrange JL, Le Pechoux C, Lebeau B, Chastang C. A controlled study of postoperative radiotherapy for patients with completely resected non small cell lung carcinoma. Cancer 1999;86:265-273.
9. Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small cell lung carcinoma. J Clin Oncol 2001;19:3912-3917.
10. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer 2005; 48:389-397.
11. Perry MC, Kohman LJ, Bonner JA, Gu L, Wang X, Vokes EE, Green MR. A phase III study of surgical resection and paclitaxelycarboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer 2007;8:268-272.
12. Douillard JY. Impact of radiation on survival after complete resection of non-small cell lung cancer: descriptive analysis in the randomized adjuvant chemotherapy trial ANITA 1(abstract). Int J Radiat Oncol Biol Phys 2006;66(Suppl):S2.
13. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, Pairolero PC, Allen MS, Lange CM, Li H. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997;64:1402-1407.
14. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001;34:29-36.